Table 3. Multivariable analysis for the risk factors associated with fatty liver progression.
| Variable | Univariable | Multivariable | ||
|---|---|---|---|---|
| HR (95% CI) | P-value | HR (95% CI) | P-value | |
| Treatment modality | ||||
| Control | 1 (Reference) | 1 (Reference) | ||
| Aromatase inhibitor | 1.331 (0.985–1.798) | 0.063 | 1.230 (0.839–1.803) | 0.289 |
| Tamoxifen | 1.744 (1.361–2.234) | <0.001 | 1.598 (1.173–2.177) | 0.003 |
| Age (year) | 1.002 (0.993–1.012) | 0.618 | ||
| BMI (kg/m2) | 1.061 (1.036–1.087) | <0.001 | 1.083 (1.052–1.114) | <0.001 |
| Diabetes | 1.197 (0.843–1.701) | 0.315 | ||
| Hypertension | 1.214 (0.959–1.537) | 0.107 | ||
| Cancer stage | ||||
| ≤1 | 1 (Reference) | |||
| 2 | 1.230 (1.003–1.507) | 0.047 | ||
| ≥3 | 1.204 (0.857–1.693) | 0.284 | ||
| Pathology | ||||
| Invasive ductal carcinoma | 1 (Reference) | |||
| Ductal carcinoma in situ | 1.271 (0.915–1.764) | 0.153 | ||
| Mucinous carcinoma | 1.300 (0.761–2.22) | 0.337 | ||
| Infiltrating lobular carcinoma | 1.051 (0.576–1.917) | 0.871 | ||
| Intraductal papilloma | 2.187 (1.199–3.991) | 0.011 | ||
| Tubular carcinoma | 0.878 (0.123–6.252) | 0.896 | ||
| Apocrine carcinoma | 0.923 (0.13–6.574) | 0.936 | ||
| Squamous carcinoma | 1.005 (0.141–7.16) | 0.996 | ||
| Medullary carcinoma | 0.900 (0.289–2.807) | 0.856 | ||
| Others | 0.820 (0.204–3.294) | 0.780 | ||
| Lymph node metastasis | 1.115 (0.907–1.37) | 0.303 | ||
| ER (Intermediate or High) | 1.459 (1.17–1.82) | 0.001 | ||
| PR (Intermediate or High) | 1.621 (1.312–2.002) | <0.001 | 1.395 (1.049–1.857) | 0.022 |
| HER2 (Intermediate or High) | 1.215 (0.998–1.479) | 0.052 | ||
| Chemotherapy | 0.827 (0.664–1.029) | 0.089 | ||
| Radiotherapy | 1.092 (0.9–1.326) | 0.372 | ||
| FSH | 0.995 (0.991–0.999) | 0.012 | 0.995 (0.991–0.999) | 0.024 |
| Platelet | 1.002 (1.001–1.003) | 0.004 | 1.002 (1.001–1.004) | 0.004 |
| AST | 1.004 (0.998–1.011) | 0.207 | ||
| ALT | 1.004 (0.999–1.009) | 0.115 | ||
| Serum albumin | 0.902 (0.729–1.115) | 0.339 | ||
| Total bilirubin | 0.620 (0.419–0.917) | 0.017 | ||
| Total cholesterol | 0.999 (0.997–1.002) | 0.668 | ||
| Triglyceride | 1.001 (1–1.002) | 0.002 | ||
| HDL-cholesterol | 0.983 (0.975–0.992) | <0.001 | ||
| LDL-cholesterol | 1 (0.996–1.003) | 0.972 | ||
| Fasting blood glucose | 1.003 (1–1.006) | 0.088 | ||
| BARD | 1.044 (0.921–1.184) | 0.503 | ||
| NFS | 0.947 (0.876–1.024) | 0.170 | ||
| FIB-4 | 0.937 (0.83–1.056) | 0.287 | ||
Abbreviations: HR, hazard ratio; CI, confidence interval; ER, estrogen receptor; PR, progesterone receptor; HER2, Human epidermal growth factor receptor 2; FSH, follicle stimulating hormone; AST, aspartate aminotransferase; ALT, alanine aminotransferase; HDL, high-density lipoprotein; LDL, low-density lipoprotein; NFS, nonalcoholic fatty liver disease fibrosis score; FIB-4, fibrosis-4.